Key Points
- CEO Jeffrey Dayno sold 25,933 shares on December 12 at an average price of $40.11, generating proceeds of about $1.04 million (SEC filing).
- Harmony reported Q3 EPS of $0.87, missing consensus by $0.05 while beating revenue estimates with $239.5 million; the company has a market cap of about $2.23 billion and a PE ratio near 12.2.
- Institutional investors own roughly 86.23% of the stock, and analysts rate HRMY as a "Moderate Buy" with an average price target around $45.63 (mixed buy/hold coverage).
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) CEO Jeffrey Dayno sold 25,933 shares of the business's stock in a transaction on Friday, December 12th. The shares were sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Harmony Biosciences Stock Performance
HRMY stock opened at $38.72 on Thursday. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.52 and a 1-year high of $40.93. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18. The firm has a market cap of $2.23 billion, a PE ratio of 12.23, a P/E/G ratio of 0.49 and a beta of 0.80. The business's 50-day moving average price is $32.73 and its two-hundred day moving average price is $33.38.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.05). Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%.The business had revenue of $239.46 million for the quarter, compared to analyst estimates of $222.68 million. As a group, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.
Hedge Funds Weigh In On Harmony Biosciences
Several hedge funds and other institutional investors have recently made changes to their positions in HRMY. Boston Partners acquired a new position in shares of Harmony Biosciences during the 2nd quarter worth $19,398,000. Arrowstreet Capital Limited Partnership raised its stake in Harmony Biosciences by 127.6% during the second quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company's stock worth $28,658,000 after acquiring an additional 508,498 shares in the last quarter. New Vernon Capital Holdings II LLC raised its stake in Harmony Biosciences by 3,219.0% during the first quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company's stock worth $16,211,000 after acquiring an additional 473,708 shares in the last quarter. UBS Group AG lifted its holdings in shares of Harmony Biosciences by 213.3% in the third quarter. UBS Group AG now owns 503,081 shares of the company's stock worth $13,865,000 after acquiring an additional 342,505 shares during the last quarter. Finally, Nomura Holdings Inc. boosted its stake in shares of Harmony Biosciences by 382.3% in the 2nd quarter. Nomura Holdings Inc. now owns 422,919 shares of the company's stock valued at $13,364,000 after purchasing an additional 335,237 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms recently weighed in on HRMY. Needham & Company LLC reissued a "buy" rating and issued a $42.00 target price on shares of Harmony Biosciences in a research note on Monday, November 24th. Oppenheimer restated an "outperform" rating and issued a $62.00 price target on shares of Harmony Biosciences in a research note on Monday, November 24th. Wall Street Zen raised Harmony Biosciences from a "hold" rating to a "buy" rating in a report on Saturday, December 13th. HC Wainwright reissued a "buy" rating on shares of Harmony Biosciences in a report on Wednesday, December 3rd. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of Harmony Biosciences from $54.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Harmony Biosciences has an average rating of "Moderate Buy" and an average price target of $45.63.
View Our Latest Analysis on Harmony Biosciences
Harmony Biosciences Company Profile
(
Get Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
